株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

淋病:パイプライン製品の分析

Gonorrhea - Pipeline Review, H1 2015

発行 Global Markets Direct 商品コード 302503
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
淋病:パイプライン製品の分析 Gonorrhea - Pipeline Review, H1 2015
出版日: 2015年05月13日 ページ情報: 英文 49 Pages
概要

淋病は、性感染症の一種で、男性にも女性にも感染の危険があり、特に尿道、直腸、食道、さらに女性には子宮にも多くの感染が認められます。

当レポートでは、淋病治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

淋病の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

淋病:企業で開発中の治療薬

淋病:大学/機関で研究中の治療薬

淋病:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

淋病:企業で開発中の製品

淋病:大学/機関で研究中の製品

淋病の治療薬開発に従事している企業

  • Melinta Therapeutics, Inc
  • Cubist Pharmaceuticals, Inc.
  • Genocea Biosciences, Inc.

淋病:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • delafloxacin
  • solithromycin
  • 淋病ワクチン
  • 細菌およびウイルス感染症の治療薬
  • IL 12 NanoCap

淋病:最近のパイプライン動向

淋病:休止中のプロジェクト

淋病:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6774IDB

Summary

Global Markets Direct's, 'Gonorrhea - Pipeline Review, H1 2015', provides an overview of the Gonorrhea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gonorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gonorrhea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gonorrhea
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gonorrhea and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gonorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gonorrhea pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gonorrhea
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gonorrhea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gonorrhea Overview
  • Therapeutics Development
    • Pipeline Products for Gonorrhea - Overview
    • Pipeline Products for Gonorrhea - Comparative Analysis
  • Gonorrhea - Therapeutics under Development by Companies
  • Gonorrhea - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Gonorrhea - Products under Development by Companies
  • Gonorrhea - Companies Involved in Therapeutics Development
    • Genocea Biosciences, Inc.
    • Melinta Therapeutics, Inc
    • Merck & Co., Inc.
    • PTC Therapeutics, Inc.
  • Gonorrhea - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • edodekin alfa SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gonorrhea vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PTC-672 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Gonorrhea - Recent Pipeline Updates
  • Gonorrhea - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gonorrhea, H1 2015
  • Number of Products under Development for Gonorrhea - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Late Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Gonorrhea - Pipeline by Genocea Biosciences, Inc., H1 2015
  • Gonorrhea - Pipeline by Melinta Therapeutics, Inc, H1 2015
  • Gonorrhea - Pipeline by Merck & Co., Inc., H1 2015
  • Gonorrhea - Pipeline by PTC Therapeutics, Inc., H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Gonorrhea Therapeutics - Recent Pipeline Updates, H1 2015
  • Gonorrhea - Dormant Projects, H1 2015

List of Figures

  • Number of Products under Development for Gonorrhea, H1 2015
  • Number of Products under Development for Gonorrhea - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Early Stage Products, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top